CARsgen Completes Series A Financing
- Dr. Li Zonghai gave speech at CAR-T TCR 2016 Annual Summit
- CARsgen Therapeutics Completes $30 Million Series B Financing
- Adoptive Immunotherapy using T Lymphocytes Redirected to Glypican-3 for the Treatment of Lung Squamous Cell Carcinoma
- CARsgen Enters into Partnership Agreement with Shanghai Cancer Institute and to Develop Novel CAR-T Technology
- Development of T cells redirected to glypican-3 for the treatment of hepatocellular carcinoma.